Integer (NYSE:ITGR) Stock Price Down 2.2% – Time to Sell?

Integer Holdings Co. (NYSE:ITGR)’s share price dropped 2.2% during trading on Friday . The stock traded as low as $115.28 and last traded at $115.82. Approximately 456,285 shares traded hands during trading, an increase of 45% from the average daily volume of 315,621 shares. The stock had previously closed at $118.40.

Analyst Ratings Changes

ITGR has been the topic of several research reports. KeyCorp raised their price target on Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Wells Fargo & Company restated an “overweight” rating and set a $160.00 price target on shares of Integer in a research note on Tuesday, December 3rd. Oppenheimer lowered Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. Truist Financial lifted their target price on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, Citigroup lifted their target price on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Integer currently has a consensus rating of “Moderate Buy” and a consensus target price of $149.00.

Integer Price Performance

The firm has a market cap of $3.96 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 1.72 and a beta of 1.24. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. The stock has a 50 day moving average price of $134.11 and a two-hundred day moving average price of $132.72.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The business had revenue of $449.50 million for the quarter, compared to analysts’ expectations of $446.28 million. As a group, equities analysts expect that Integer Holdings Co. will post 6.01 earnings per share for the current year.

Institutional Investors Weigh In On Integer

A number of large investors have recently modified their holdings of ITGR. Capital Research Global Investors lifted its holdings in shares of Integer by 16.0% during the fourth quarter. Capital Research Global Investors now owns 1,410,803 shares of the medical equipment provider’s stock worth $186,960,000 after purchasing an additional 194,895 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Integer by 1.2% during the third quarter. Geode Capital Management LLC now owns 764,528 shares of the medical equipment provider’s stock worth $99,408,000 after purchasing an additional 9,421 shares during the period. Loomis Sayles & Co. L P lifted its holdings in shares of Integer by 3.8% during the fourth quarter. Loomis Sayles & Co. L P now owns 558,715 shares of the medical equipment provider’s stock worth $74,041,000 after purchasing an additional 20,688 shares during the period. Congress Asset Management Co. lifted its holdings in shares of Integer by 2.0% during the fourth quarter. Congress Asset Management Co. now owns 498,350 shares of the medical equipment provider’s stock worth $66,041,000 after purchasing an additional 9,565 shares during the period. Finally, Driehaus Capital Management LLC lifted its holdings in shares of Integer by 5.5% during the fourth quarter. Driehaus Capital Management LLC now owns 451,464 shares of the medical equipment provider’s stock worth $59,828,000 after purchasing an additional 23,706 shares during the period. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.